Carvykti
Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies
Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies.
Johnson & Johnson Oncology Unit Revenues Jump 16 Percent in Q2
J&J reported a nearly 60 percent growth in sales of its top-selling precision oncology drug, the CAR T-cell therapy Carvykti, in Q2 2024 compared a year ago.
Gilead, Arcellx Outline Plans for Phase III Anito-Cel Multiple Myeloma Trial
The partners will compare the activity of the BCMA-directed autologous CAR T-cell therapy against standard treatment in refractory patients.
Janssen, Legend Biotech's Carvykti Nets EU Approval in Early-Line Multiple Myeloma
The approval makes the CAR T-cell therapy available to advanced multiple myeloma patients earlier in the course of their treatment.
FDA Requires Boxed Warning of Secondary Cancer Risk for Autologous CAR T-Cell Therapies
The requirement comes after FDA investigated data showing patients developed secondary T-cell malignancies after CD19- and BCMA-directed CAR T-cell therapies.